| Infectious Diseases - Researchers map malaria parasites in unprecedented cellular detail |
|
|
|
|
| |
|
| |
The latest infectious diseases news from News Medical |
|
|
|
 | | |  A Convenient Method to Evaluate Vaccine Efficacy against SARS-CoV-2 Variants of Concern
While a growing number of people are getting vaccinated to acquire protection against SARS-CoV-2, the original wild-type virus is evolving to acquire increased fitness that may help evade vaccine-induced immune surveillance. In face of this “Red Queen” challenge, how strong the current vaccine protection is against the circulating and emerging variants of the virus becomes a primary concern.
ACROBio is excited and proud to introduce a series of neutralizing antibody titer kits specifically designed for the SARS-CoV-2 variants of concern (VOC) to you!
- Based on a competitive ELISA method
- Detect neutralizing antibodies which can specifically inhibit the binding of mutated RBD/ Spike to ACE2
- High throughput and convenient to evaluate vaccine efficacy against SARS-CoV-2 VOC
| |
|
|
| | | | |  According to the World Health Organization (WHO), COVID-19 long-haulers are people who experience symptoms such as body ache, fatigue, shortness of breath, headache, difficulty concentrating, loss of taste or smell, or other health issues long after they test negative for the virus. It can be defined as having serious and prolonged symptoms three months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. | | | | |  A recent study conducted by a team of scientists in the Netherlands has revealed that while severely affected hospitalized COVID-19 patients and vaccinated individuals are capable of neutralizing the B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2, a significant proportion of non-hospitalized patients with less severe COVID-19 remain susceptible to these viral variants. | | | | |  Researchers found different groups of symptoms persisting after coronavirus disease 2019 (COVID-19), with fatigue and higher IL-6 levels common in women. About 75% of the patients they treated were women, indicating a link between sex hormones and immune response. | |
|
|
|
|
|
|
|
